102.46MMarket Cap-422P/E (TTM)
1.080High1.030Low972.44KVolume1.080Open1.060Pre Close1.02MTurnover1.07%Turnover RatioLossP/E (Static)99.48MShares3.80052wk High-0.45P/B93.33MFloat Cap0.33352wk Low--Dividend TTM90.61MShs Float68.550Historical High--Div YieldTTM4.72%Amplitude0.333Historical Low1.043Avg Price1Lot Size
FibroGen Stock Forum
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
Pamrevlumab
•Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in mid-2024, reflecting PanCAN’s updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical Monitoring Committee.•Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic can...
No comment yet